Biogen (BIIB) closed at $232.65 on Oct 16, 2026, down 1.1% on the day. The stock is up 6.2% over the past month, up 16.4% over three months, up 32.2% year to date and up 61.9% over the past year. It trades 3.5% below its 52-week high of $240.99 and 68.6% above its 52-week low of $138.00. The close sits above its 50-day moving average ($219.71) and above its 200-day moving average ($197.83).
NextPick tracks BIIB in its Biotech basket alongside VRTX, MRNA, REGN, ALNY and BNTX. As of Oct 16, 2026, the basket's money-flow score is -8 (neutral), and the basket is down 3.4% over five sessions. Over the past month BIIB ranks 4th of 17 basket members by price change.
BIIB is scheduled to report earnings on Oct 28, 2026.
Biogen is scheduled to report on Oct 28, 2026.
Yes — the Oct 16, 2026 close of $232.65 is 17.6% above the 200-day average of $197.83.
BIIB closed 3.5% below its 52-week high of $240.99.
NextPick groups BIIB with VRTX, MRNA, REGN, ALNY and BNTX in its Biotech basket.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
